Fig 1: Screening and establishment for DNAm-driven signature associated with prognosis. (a) Survival analysis for CLDN1, ABCC5, and CSTA expressions in LUSC. (b) A 10-foldcross-validation for tuning parameter selection in the Least Absolute Shrinkage and Selection Operator model. Partial likelihood deviance is plotted against log (?), where ? is the tuning parameter. Dotted vertical lines were drawn at the optimal values by minimum criteria and 1-s.e. criteria. (c) Comparison of OS between the high-risk and low-risk score groups. (d) Time-dependent receiver operating characteristic analysis was performed to evaluate the accuracy of the prognostic signature. (e) Univariate and multivariate regression analysis was performed to identify significantly predictive factors associated with OS. OS, overall survival (days); CLDN1, Claudin 1; ABCC5, ATP-binding cassette subfamily C member 5; CSTA, Cystatin A.
Fig 2: Inhibition of ABCC5, CLDH1, and CSTA reduced the carcinogenesis of NSCLC cells. (a) Representative images of EDU staining for Control, siABCC5, siCLDN1, and siCSTA groups. Magnification, ×200. (b) Comparison of colonies number among control, siABCC5, siCLDN1, and siCSTA groups. (c) Representative images of invasive ability comparison among Control, siABCC5, siCLDN1, and siCSTA groups. Magnification, ×100. Data are displayed as the mean ± standard deviation. Student's t-test was performed. ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. NSCLC, non-small-cell lung cancer; EDU, 5-ethynyl-2′-deoxyuridine; ABCC5, ATP-binding cassette subfamily C member 5; CLDN1, Claudin 1; CSTA, Cystatin A.
Fig 3: Down-regulation of HOTAIR decreased the resistance of C666-1/DDP and CNE2/DDP cells to DDP. HOTAIR siRNA was transfected into C666-1/DDP and CNE2/DDP cells, following transfection for 48 h, the interference efficiencies were detected with qPCR (a). The IC50 values of DDP (b, c), the protein levels of MDR1, MRP5, LRP1and ABCB1 (d, e) were detected by Western blotting. *p < 0.05, **p < 0.01.
Fig 4: ABCC5, CLDN1, and CSTA expression in LUSC and paracancerous tissues. (a) mRNA expression levels of ABCC5, CLDN1, and CSTA in LUSC and paracancerous tissues. (b) Protein expression levels of ABCC5, CLDN1, and CSTA in LUSC and paracancerous tissues. (c) Representative images of immunohistochemistry staining for ABCC5, CLDN1, and CSTA in LUSC and paracancerous tissues. Magnification, ×200. Data are displayed as the mean ± standard deviation. Student's t-test was performed.*P < 0.05 and ***P < 0.001. LUSC, lung squamous cell carcinoma; CLDN1, Claudin 1; ABCC5, ATP-binding cassette subfamily C member 5; CSTA, Cystatin A.
Supplier Page from Abcam for Anti-MRP5 antibody [6C6]